MCID: UTR037
MIFTS: 25

Uterine Corpus Sarcoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Sarcoma

MalaCards integrated aliases for Uterine Corpus Sarcoma:

Name: Uterine Corpus Sarcoma 12 15 73
Sarcoma of Corpus Uteri 12
Sarcoma of Uterus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5165
NCIt 50 C6339
SNOMED-CT 68 254877001
UMLS 73 C0338113

Summaries for Uterine Corpus Sarcoma

Disease Ontology : 12 An uterine corpus cancer that is located in the muscles of the uterus or located in other tissues that support the uterus.

MalaCards based summary : Uterine Corpus Sarcoma, also known as sarcoma of corpus uteri, is related to uterus leiomyosarcoma and uterine sarcoma. An important gene associated with Uterine Corpus Sarcoma is SMUG1 (Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1). The drugs Gemcitabine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include the muscles of the uterus or, uterus and lung.

Related Diseases for Uterine Corpus Sarcoma

Diseases related to Uterine Corpus Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 uterus leiomyosarcoma 11.1
2 uterine sarcoma 11.1
3 uterine carcinosarcoma 11.0
4 sarcoma 10.0
5 endometrial stromal sarcoma 10.0

Graphical network of the top 20 diseases related to Uterine Corpus Sarcoma:



Diseases related to Uterine Corpus Sarcoma

Symptoms & Phenotypes for Uterine Corpus Sarcoma

Drugs & Therapeutics for Uterine Corpus Sarcoma

Drugs for Uterine Corpus Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
2
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
5
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
6
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Not Applicable 33069-62-4 36314
7
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
8
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
9
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
10
Mesna Approved, Investigational Phase 3 3375-50-6 598
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Cyproheptadine Approved Phase 3 129-03-3 2913
13
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
14
Bevacizumab Approved, Investigational Phase 3 216974-75-3
15
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
16
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
17 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
18
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
19 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Albumin-Bound Paclitaxel Phase 3,Phase 2,Not Applicable
21 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
22 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
23 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
24 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
25 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Liver Extracts Phase 3,Phase 1,Phase 2,Not Applicable
29 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
30 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
32 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
35 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
36 Central Nervous System Depressants Phase 3
37 Adjuvants, Anesthesia Phase 3
38 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
39 Mitogens Phase 3,Phase 2
40 Narcotics Phase 3
41 Analgesics, Opioid Phase 3
42 Anesthetics Phase 3
43 Anesthetics, General Phase 3
44 Anesthetics, Intravenous Phase 3
45 Endothelial Growth Factors Phase 3,Phase 2
46 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Gastrointestinal Agents Phase 3,Phase 2
48 Antibodies Phase 3,Phase 2
49 Immunoglobulins Phase 3,Phase 2
50 Antibodies, Monoclonal Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
2 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
3 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
4 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
5 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
6 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
10 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
11 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
12 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
13 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
14 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3 prasterone
15 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
16 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
17 Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma Unknown status NCT01303094 Phase 2 Trabectedin
18 Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers Unknown status NCT02052128 Phase 1, Phase 2 onapristone
19 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
20 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
21 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
22 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
23 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
24 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
25 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
26 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Completed NCT01220609 Phase 2 Ixabepilone
27 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01168232 Phase 2 Ixabepilone
28 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
29 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
30 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
31 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2 Thalidomide
32 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
33 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
34 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
35 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
36 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2 carboplatin;paclitaxel
37 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
38 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2 trabectedin
39 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
40 Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00003778 Phase 2 dolastatin 10
41 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Completed NCT01764802 Phase 2
42 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery Completed NCT01553539 Phase 2 therapeutic angiotensin-(1-7)
43 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
44 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
45 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
46 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
47 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
48 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
49 Chemotherapy in Treating Patients With Advanced Sarcoma Completed NCT00002526 Phase 2 doxorubicin hydrochloride;ifosfamide
50 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate

Search NIH Clinical Center for Uterine Corpus Sarcoma

Genetic Tests for Uterine Corpus Sarcoma

Anatomical Context for Uterine Corpus Sarcoma

The Foundational Model of Anatomy Ontology organs/tissues related to Uterine Corpus Sarcoma:

19
The Muscles Of The Uterus Or

MalaCards organs/tissues related to Uterine Corpus Sarcoma:

41
Uterus, Lung, Brain, T Cells, Endothelial, Prostate, Kidney

Publications for Uterine Corpus Sarcoma

Articles related to Uterine Corpus Sarcoma:

# Title Authors Year
1
Genomic landscape of endometrial stromal sarcoma of uterus. ( 26429873 )
2015
2
Endometrial stromal sarcoma of uterus with metastasis to the lung and brain. ( 22987911 )
2012
3
Endometrial stromal sarcoma of uterus. ( 21820965 )
2011
4
Mixed low grade and high grade endometrial stromal sarcoma of uterus: differences on immunohistochemistry and chromosome in situ hybridisation. ( 8813967 )
1996

Variations for Uterine Corpus Sarcoma

Expression for Uterine Corpus Sarcoma

Search GEO for disease gene expression data for Uterine Corpus Sarcoma.

Pathways for Uterine Corpus Sarcoma

GO Terms for Uterine Corpus Sarcoma

Sources for Uterine Corpus Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....